Scientists have found a small molecule, called ISRIB, that was able to reduce fibrosis (scarring) and other disease-related features in mice with induced pulmonary fibrosis (PF). ISRIB successfully enhanced the repair process in lung cells that is altered in PF, especially…
Progressive lung diseases like pulmonary fibrosis cause ripple effects throughout the body. In PF, lung scarring prevents the organs from exchanging gases correctly, resulting in oxygen deficits known as hypoxemia and hypoxia. Chronic hypoxemia, or low oxygen levels in the blood, affects all parts of the body.
An experimental therapy that proved ineffective in treating HIV infections now has shown promising potential at preventing or limiting pulmonary fibrosis (PF) caused by SARS-CoV-2, the virus that causes COVID-19. That finding, from a mouse model of induced PF, was detailed in the study  “Targeting RUNX1…
While you can’t predict an emergency, it helps to be prepared for one. Most young adults haven’t had to think about whom to notify during a medical emergency, but I have as a result of my idiopathic pulmonary fibrosis. Two years ago, I published a column about the importance for…
My mom, Diana, relied on a plug-in oxygen machine to breathe, and the power was going to be shut off for days. This was back in the late summer of 2019, when she was still on the lung…
DWN12088, an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase 1 clinical trial that enrolled healthy volunteers. Daewoong Pharmaceutical, the therapy’s developer, now plans to start a Phase 2 trial later this year. “We…
High-dose AP01 (inhaled pirfenidone) largely prevented lung function decline and was safe and well-tolerated during the first 24 weeks of a Phase 1/2 clinical study testing its use in patients with idiopathic pulmonary fibrosis (IPF). Avalyn Pharma, the therapy’s developer, presented the results at the 2021…
As part of the worldwide commemoration of Clinical Trials Day, held each year on May 20, the Pulmonary Fibrosis Foundation (PFF) is urging people with pulmonary fibrosis (PF) to join ongoing clinical studies. In its call for participants, the PFF highlighted how patient involvement is the “most important…
Idiopathic pulmonary fibrosis (IPF) patients showing greater changes in blood cell ratios often used as markers of inflammation are at higher risk of lung function decline, respiratory hospitalization, and death, according to a post-hoc analysis of data from several Phase 3 clinical trials. Notably, these associations were more pronounced…
Stories have been a catalyst for conversation for centuries. Generations of families are often weaved together by the narrative of a loved one’s past, and by the stories that have shaped our evolution. There is so much to learn through the stories of those who came before us. As a…
Get regular updates to your inbox.
